Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Roche with its 2024 acquisition of Carmot, and Pfizer, following its 2025 acquisition of Metsera, enter obesity and broaden their presence in cardiovascular/metabolic, while other large pharmaceutical companies prepare to follow later in the decade
Sakai et al., 2012
The Tirzepatide (Zepbound) segment is expected to grow at the fastest rate during the forecast period due to its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances weight loss outcomes
In ASD serotonin and IL-6 have been proposed as potential combined biomarkers since both present increased levels compared to control groups (Yang et al., 2015)
However, some Trulicity patients claim they have experienced concerning gastrointestinal problems, including bowel obstructions, pancreatitis, and gastroparesis
US$ 21.82
US$ 25.66
US$ 22.66
US$ 27.49
US$ 20.09
